The DOI matches its Crossref record; 212 of the 213 references it cites were found in a registry or an index.
Targeting IL-6 trans-signalling: past, present and future prospects
Open accessAbstract
Interleukin-6 (IL-6) is a key immunomodulatory cytokine that affects the pathogenesis of diverse diseases, including autoimmune diseases, chronic inflammatory conditions and cancer. Classical IL-6 signalling involves the binding of IL-6 to the membrane-bound IL-6 receptor α-subunit (hereafter termed ‘mIL-6R’) and glycoprotein 130 (gp130) signal-transducing subunit. By contrast, in IL-6 trans-signalling, complexes of IL-6 and the soluble form of IL-6 receptor (sIL-6R) signal via membrane-bound gp130. A third mode of IL-6 signalling — known as cluster signalling — involves preformed complexes of membrane-bound IL-6–mIL-6R on one cell activating gp130 subunits on target cells. Antibodies and small molecules have been developed that block all three forms of IL-6 signalling, but in the past decade, IL-6 trans-signalling has emerged as the predominant pathway by which IL-6 promotes disease pathogenesis. The first selective inhibitor of IL-6 trans-signalling, sgp130, has shown therapeutic potential in various preclinical models of disease and olamkicept, a sgp130Fc variant, had promising results in phase II clinical studies for inflammatory bowel disease. Technological developments have already led to next-generation sgp130 variants with increased affinity and selectivity towards IL-6 trans-signalling, along with indirect strategies to block IL-6 trans-signalling. Here, we summarize our current understanding of the biological outcomes of IL-6-mediated signalling and the potential for targeting this pathway in the clinic. This Review details the discovery of the interleukin-6 (IL-6) trans-signalling pathway and the subsequent development of biologics that specifically inhibit this pathway. Emerging evidence suggests that specifically targeting IL-6 trans-signalling can reduce pathological disease-promoting activities of IL-6 without blocking the protective actions of IL-6 in infection and tissue repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In MM cells, the JAK/STAT3 pathway is triggered by cytokines from the gp130 receptor family, such as IL-6, leukemia inhibitory factor (LIF), and oncostatin-M (OSM).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the binding of IL-6 to its receptor (IL-6R) leads to the activation of JAK1, which phosphorylates STAT3, thereby activating the JAK/STAT pathway [108].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Soluble gp130Fc, named olamkicept or TJ301, is consists of two soluble human gp130 proteins fused with the Fc of human IgG, and selectively targets the IL-6-sIL-6R complex [79].”
From The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As IL-6 classic signaling plays crucial roles in the initiation of inflammation and the host defense against pathogen infection, global blockade of IL-6 signaling may reduce the induction of hepatic acute-phase proteins upon infection, such as Listeria monocytogenes [79].”
From The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases (2024) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Self-citationHirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045 · cited 1×
“Dysregulated IL-6 signalling is a hallmark of infections, including SARS-CoV-2, that are characterized by hyperinflammation 137–145 , with high IL-6 levels in patients with COVID-19 being implicated in the depletion of CD4 + T cells, CD8 + T cells and natural killer cells 146 .”
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 2×
“Studies in IL-6-deficient mice showed that IL-6 contributes to the pathogenesis of many inflammatory diseases, including bacterial and viral infections 66 , arthritis 67,68 , experimental colitis 69 and multiple sclerosis 70 .”
Gauldie, J., Richards, C. D., Harnish, D. C., Lansdorp, P. M., & Baumann, H. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7251 · Cited by 1,635
Research works printed but not linked: 1
- Kang, S., Narazaki, M., Metwally, H. & Kishimoto, T. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 2020, 5 (2020).
Cited by
Sorted by citations
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 528
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 489
Strategies for targeting cytokines in inflammatory bowel disease
Neurath, M. F. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01008-6 · Cited by 444
The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis
Nishida, A., & Andoh, A. (2025) · Cells · doi:10.3390/cells14070488 · Cited by 315
Neutrophil diversity and function in health and disease
Zhang, F., Xia, Y., Su, J., Quan, F., Zhou, H., Li, Q., Feng, Q., Lin, C., Wang, D., & Jiang, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02049-y · Cited by 306
Sarapultsev, A., Gusev, E., Komelkova, M. V., Utepova, I. A., Luo, S., & Hu, D. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00151-1 · Cited by 254
Deep insight into cytokine storm: from pathogenesis to treatment
Nie, J., Zhou, L., Tian, W., Liu, X., Yang, L., Yang, X., Zhang, Y., Wei, S., Wang, D. W., & Wei, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02178-y · Cited by 251
New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
Soler, M. F., Abaurrea, A., Azcoaga, P., Araujo, A. M., & Caffarel, M. M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007530 · Cited by 208
Cytokines in gingivitis and periodontitis: from pathogenesis to therapeutic targets
Neurath, N., & Kesting, M. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435054 · Cited by 199
Ulcerative colitis: molecular insights and intervention therapy
Liang, Y., Li, Y., Lee, C., Yu, Z., Chen, C., & Liang, C. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00207-w · Cited by 192
The JAK-STAT pathway: from structural biology to cytokine engineering
Lv, Y., Qi, J., Babon, J. J., Cao, L., Fan, G.-H., Lang, J., Zhang, J., Mi, P., Kobe, B., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01934-w · Cited by 157
Thuya, W. L., Cao, Y., Ho, P. C., Wong, A. L., Wang, L., Zhou, J., Nicot, C., & Goh, B. C. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.01.003 · Cited by 154
STAT3 Signaling Pathway in Health and Disease
Samad, M. A., Ahmad, I., Hasan, A., Alhashmi, M. H., Ayub, A., Al-Abbasi, F. A., Kumer, A., & Tabrez, S. S. M. (2025) · MedComm · doi:10.1002/mco2.70152 · Cited by 140
Wu, Y., Sun, X., Kang, K., Yang, Y., Li, H., Zhao, A., & Niu, T. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01621-x · Cited by 115
The Microenvironment of the Pathogenesis of Cardiac Hypertrophy
Bazgir, F., Nau, J., Nakhaei‐Rad, S., Amin, E., Wolf, M. J., Saucerman, J. J., Lorenz, K., & Ahmadian, M. R. (2023) · Cells · doi:10.3390/cells12131780 · Cited by 106
Shiau, C., Cao, J., Gong, D. H., Gregory, M., Caldwell, N. J., Yin, X., Cho, J.-W., Wang, P. L., Su, J., Wang, S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01890-9 · Cited by 103
The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions
Kerkis, I., da Silva, Á. R. D. B. P., & Araldi, R. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1400533 · Cited by 94
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases
Wang, M.-J., Zhang, H.-L., Chen, F., Guo, X.-J., Liu, Q.-G., & Hou, J. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00527-1 · Cited by 84
“Soluble gp130Fc, named olamkicept or TJ301, is consists of two soluble human gp130 proteins fused with the Fc of human IgG, and selectively targets the IL-6-sIL-6R complex [79].”
BackgroundInfluentialPeña-Durán, E., García-Galindo, J. J., López-Murillo, L. D., Huerta-Huerta, A., Balleza-Alejandri, L. R., Beltrán-Ramírez, A., Anaya-Ambriz, E. J., & Suárez-Rico, D. O. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041773 · Cited by 77
Understanding interleukin 11 as a disease gene and therapeutic target
Cook, S. A. (2023) · Biochemical Journal · doi:10.1042/bcj20220160 · Cited by 70
Lacina, L., Kolář, M., Pfeiferová, L., Gál, P., & Smetana, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403570 · Cited by 69
Targeting Inflammation After Acute Myocardial Infarction
Imbesi, A., Greco, A., Spagnolo, M., Laudani, C., Raffo, C., Finocchiaro, S., Mazzone, P. M., Landolina, D., Mauro, M. S., Cutore, L., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.064 · Cited by 74
Saad, M. I., & Jenkins, B. J. (2023) · FEBS Journal · doi:10.1111/febs.16923 · Cited by 65
Self-citationAngiogenesis in Lung Cancer: Understanding the Roles of Growth Factors
Tchawe, Y. S. N., Zhilenkova, A. V., Essogmo, F. E., Uchendu, I. K., Owoicho, A. M., Fossa, L. T., Sangadzhieva, Z. D., Sanikovich, V. D., Rusanov, A. S., Pirogova, Y. N., et al. (2023) · Cancers · doi:10.3390/cancers15184648 · Cited by 64
Fibroblasts in immune responses, inflammatory diseases and therapeutic implications
Zou, A. E., Kongthong, S., Mueller, A. A., & Brenner, M. B. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01259-0 · Cited by 66
Prapiadou, S., Živković, L., Thorand, B., George, M. J., van der Laan, S. W., Malik, R., Herder, C., Köenig, W., Ueland, T., Kleveland, O., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064974 · Cited by 63
Ma, Q., Tian, J.-L., Lou, Y., Guo, R., Ma, X.-R., Wu, J., Yang, J., Tang, B.-J., Li, S., Qiu, M. S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115266 · Cited by 60
Chuangchot, N., Jamjuntra, P., Yangngam, S., Luangwattananun, P., Thongchot, S., Junking, M., Thuwajit, P., Yenchitsomanus, P., & Thuwajit, C. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01684-7 · Cited by 58
A Smart DNA Hydrogel Enables Synergistic Immunotherapy and Photodynamic Therapy of Melanoma
Yang, S. Y., Wu, J., Wang, Z., Cheng, Y. S., Zhang, R., Yao, C., & Yang, D. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202319073 · Cited by 56
Reprogram to heal: Macrophage phenotypes as living therapeutics
Ghamangiz, S., Jafari, A., Maleki, H., Azimi, H., & Mazloomi, E. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123601 · Cited by 54
De novo design of miniprotein antagonists of cytokine storm inducers
Huang, B., Coventry, B., Borowska, M. T., Arhontoulis, D. C., Expòsit, M., Abedi, M. H., Jude, K. M., Halabiya, S. F., Allen, A., Cordray, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50919-4 · Cited by 54
Părângă, T. G., Mitu, I., Tanasa, M. P., Roșu, M. F., Miftode, I.-L., Constantinescu, D., Obreja, M., Plesca, C. E., & Miftode, E. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111411 · Cited by 51
Giollabhui, N. M., Slaney, C., Hemani, G., Foley, É. M., van der Most, P. J., Nolte, I. M., Snieder, H., Smith, G. D., Khandaker, G. M., & Hartman, C. A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03372-w · Cited by 51
Wang, Y., Zhang, J., Wang, J., Zhang, Y., Sun, J., Gong, J., Yao, X., & Sun, H. (2026) · Pharmaceuticals · doi:10.3390/ph19060868 · Cited by 49
Navigating IL-6: From molecular mechanisms to therapeutic breakthroughs
Swaroop, A. K., Negi, P., Kar, A., Mariappan, E., Natarajan, J., Namboori, P. K. K., & Selvaraj, J. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.12.007 · Cited by 48
Li, L., Cao, Z., Zhang, C., Li, L., Li, Q., Liu, C., Qu, C., Luo, R., Fu, P., & Wang, Y. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202312243 · Cited by 47
Diabetic Retinopathy: New Treatment Approaches Targeting Redox and Immune Mechanisms
Tang, Q., Buonfiglio, F., Böhm, E. W., Zhang, L., Pfeiffer, N., Korb, C. A., & Gericke, A. (2024) · Antioxidants · doi:10.3390/antiox13050594 · Cited by 48
Darweesh, M. F., Mohammadi, S., Rahmati, M., Al-Hamadani, M., & Al‐Harrasi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1578202 · Cited by 51
Vella, R., Panci, D., Carini, F., Malta, G., Vieni, S., David, S., Albano, G. D., Puntarello, M., Zerbo, S., & Argo, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1682306 · Cited by 47
Elucidating the role of gut microbiota metabolites in diabetes by employing network pharmacology
Yao, W., Huo, J., Ji, J., Liu, K., & Tao, P. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01033-0 · Cited by 46
Osteoarthritis: molecular pathogenesis and potential therapeutic options
Zhang, Y., Han, Y., Sun, Y., Hao, L., Gao, Y., Ye, J., Wang, H., Zhang, T., Liu, Y., & Yang, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02556-6 · Cited by 48
IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention
Schumertl, T., Lokau, J., & Garbers, C. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s485684 · Cited by 45
Self-citationCasanova, J., Peel, J. N., Donadieu, J., Neehus, A., Puel, A., & Bastard, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-01815-y · Cited by 41
Neutrophil Extracellular Traps in ST-Segment Elevation Myocardial Infarction
Kindberg, K. M., Broch, K., Andersen, G. Ø., Anstensrud, A. K., Åkra, S., Woxholt, S., Tøllefsen, I. M., Ueland, T., Amundsen, B. H., Kløw, N., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101193 · Cited by 41
Expert Perspective: Diagnosis and Treatment of Castleman Disease
Chen, L. Y. C., Zhang, L., & Fajgenbaum, D. C. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43269 · Cited by 41
The Role of IL-6 in Ischemic Stroke
Pawluk, H., Woźniak, A., Tafelska‐Kaczmarek, A., Kosinska, A., Pawluk, M., Sergot, K., Grochowalska, R., & Kołodziejska, R. (2025) · Biomolecules · doi:10.3390/biom15040470 · Cited by 40
Meng, L., Li, J., Zhu, Y., Ruan, H., Li, J., Xu, F., Liu, R., Yang, T., Shi, Y., Feng, N., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.08.021 · Cited by 39
Donniacuo, A., Mauro, A., Cardamone, C., Basile, A., Manzo, P., Dimitrov, J., Cammarota, A. L., Marzullo, L., Triggiani, M., Turco, M. C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188921 · Cited by 39
Interleukin-6 in Hepatocellular Carcinoma: A Dualistic Point of View
Nenu, I., Toadere, T. M., Topor, I., Țichindeleanu, A., Bondor, D. A., Trella, Ș. E., Sparchez, Z. A., & Filip, G. A. (2023) · Biomedicines · doi:10.3390/biomedicines11102623 · Cited by 37
Pathogenic Role of Cytokines in Rheumatoid Arthritis
Fujimoto, S., & Niiro, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186409 · Cited by 37
Clinical translation and landscape of superparamagnetic iron oxide nanoparticles
Li, Y., Barmin, R. A., Zhang, R., Kiessling, F. M., Lammers, T., & Pallares, R. M. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115756 · Cited by 36
The “cytokine storm” in infection and sepsis: win the battle but lose the war
Fan, J., Li, Q.-Y., Feng, X.-F., Huang, S., Wang, R., Liao, F.-Y., Liu, D., Liu, W.-Y., Sun, J.-H., Zhang, H.-C., et al. (2026) · Military Medical Research · doi:10.1186/s40779-025-00678-0 · Cited by 35
Hoffman, J. M., Robinson, R. L., Greenway, G., Glass, J., Budkin, S., & Sharma, S. (2023) · Experimental Eye Research · doi:10.1016/j.exer.2023.109721 · Cited by 33
Immune markers of severe acute pancreatitis
Lee, P. J., Papachristou, G. I., Speake, C., & Lacy‐Hulbert, A. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001053 · Cited by 33
Taylor, P. C., Feist, E., Pope, J. E., Nash, P. T., Sibilia, J., Caporali, R., & Balsa, A. (2024) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x241283340 · Cited by 33
Xu, J., Wakai, M., Xiong, K., Yang, Y., Prabakaran, A., Wu, S. P., Ahrens, D., Molina‐Portela, M. D. P., Ni, M., Bai, Y., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115403 · Cited by 35
IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk
Zhang, L., Omarov, M., Xu, L., deGoma, E. M., Natarajan, P., & Georgakis, M. K. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00700-7 · Cited by 32
Interleukin-6: An Under-Appreciated Inducer of Thermogenic Adipocyte Differentiation
Radványi, Á., & Rőszer, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052810 · Cited by 31
Huang, Z., Lin, D., Zhang, H., Yang, M., Chen, J., Ding, X., Dai, S., Hong, Y., Liang, G., Li, Q., et al. (2024) · Immunology · doi:10.1111/imm.13786 · Cited by 31
Interventions in cytokine signaling: novel horizons for psoriasis treatment
Li, L., Liu, J., Lu, J., Wu, J., Zhang, X., Ma, T., Wu, X., Zhu, Q., Chen, Z., & Tai, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573905 · Cited by 30
Adipose tissue-derived mediators of systemic inflammation and metabolic control
Alexaki, V. I. (2024) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2024.100560 · Cited by 29
Wu, H., Liao, B., Ji, T., Ma, K., Luo, Y., & Zhang, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1496869 · Cited by 29
Role of Ischemia/Reperfusion and Oxidative Stress in Shock State
Vázquez-Galán, Y. I., Guzmán-Silahua, S., Trujillo-Rangel, W. Á., & Rodríguez-Lara, S. Q. (2025) · Cells · doi:10.3390/cells14110808 · Cited by 29
Berger, M., Baliker, M., van Gelder, T., Böhmig, G. A., Mannon, R. B., Kumar, D., Chadban, S. J., Nickerson, P. W., Lee, L. A., & Djamali, A. (2023) · Transplantation · doi:10.1097/tp.0000000000004822 · Cited by 28
Presicce, P., Roland, C., Senthamaraikannan, P., Cappelletti, M., Hammons, M., Miller, L. A., Jobe, A. H., Chougnet, C. A., DeFranco, E., & Kallapur, S. G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1416162 · Cited by 28
Metabolic Syndrome and Psoriasis: Pivotal Roles of Chronic Inflammation and Gut Microbiota
Secchiero, P., Rimondi, E., Marcuzzi, A., Longo, G., Papi, C., Manfredini, M., Fields, M., Caruso, L., Caprio, R. D., & Balato, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158098 · Cited by 28
Sun, G., Fu, X., Zheng, Y., Hong, G., Liu, Z., Luo, B., Lei, J., Lv, D., Chang, M., Xiao, Y., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00896-0 · Cited by 28
DePaula-Silva, A. B. (2024) · Viruses · doi:10.3390/v16010119 · Cited by 29
Yuan, C., Ye, Y., Hu, E., Xie, R., Lu, B., Yu, K., Ding, W., Wang, W., Lan, G., & Lu, F. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122058 · Cited by 28
Interleukin-6 drives endothelial glycocalyx damage in COVID-19 and bacterial sepsis
Drost, C. C., Rovas, A., Osiaevi, I., Schughart, K., Lukasz, A. H., Linke, W. A., Pavenstädt, H. J., & Kümpers, P. (2024) · Angiogenesis · doi:10.1007/s10456-024-09916-w · Cited by 27
Metwally, H., Elbrashy, M. M., Ozawa, T., Okuyama, K., White, J. T., Tulyeu, J., Søndergaard, J. N., Wing, J. B., Muratsu, A., Matsumoto, H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402226121 · Cited by 27
Interlinking pathways: a narrative review on the role of IL-6 in cancer and atherosclerosis
Cau, R., & Saba, L. (2024) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-24-344 · Cited by 27
Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies
Park, E., & Lee, C. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01150-6 · Cited by 27
Advancements in the study of IL-6 and its receptors in the pathogenesis of gout
Zhang, Z., Wang, P., Xiong, Q., Xu, S., Kang, D. W., He, Z., Yao, C., & Jian, G. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156705 · Cited by 27
Ford, M. L., Reza, M. I., Ruwanpathirana, A., Sathish, V., & Britt, R. D. (2025) · Immunological Reviews · doi:10.1111/imr.70007 · Cited by 27
The role of interleukin‐6 family cytokines in cancer cachexia
Agca, S., & Kır, S. (2024) · FEBS Journal · doi:10.1111/febs.17224 · Cited by 26
Lopresti, L., Tatangelo, V., Baldari, C. T., & Patrussi, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418527 · Cited by 27
Inflammation‐Activatable Nanoscavengers for Sustainable Cell‐Free DNA Capture and Cleavage
Yin, M., Ge, C., Zhou, Y., Zhou, R., Yang, Y., Qian, Y., He, J., Shen, J., & Yin, L. (2025) · Advanced Materials · doi:10.1002/adma.202504557 · Cited by 25
Robinson, G. I., Li, D., Wang, B., Zahoruiko, Y., Gerasymchuk, M., Hudson, D., Kovalchuk, O., & Kovalchuk, I. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080427 · Cited by 24
Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles
Chigbu, D. I., Karbach, N. J., Abu, S. L., & Hehar, N. K. (2024) · Life · doi:10.3390/life14030350 · Cited by 24
Goshi, N., Lam, D., Bogguri, C., George, V. K., Sebastian, A., Cadena, J., Leon, N. F., Hum, N. R., Weilhammer, D. R., Fischer, N. O., et al. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1512591 · Cited by 24
Xiao, M., Chen, Y., & Mu, J. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114937 · Cited by 23
Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease
Luthra, N., Mehta, N., Munoz, M. J., Fantuzzi, G., Lamotte, G. J., Haus, J. M., McFarland, N. R., Tansey, M. G., González-Latapí, P., Caraveo, G., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01042-8 · Cited by 24
Akkerman, R., Oerlemans, M. M. P., Ferrari, M. D. L., Fernández‐Lainez, C., Walvoort, M. T. C., & de Vos, P. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.123017 · Cited by 22
Lokau, J., Garbers, Y., Vicente, M. M., Dittrich, A., Meltendorf, S., Lingel, H., Münster-Kühnel, A. K., Brunner-Weinzierl, M. C., & Garbers, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1488745 · Cited by 20
Self-citationLi, X., & Zhao, C. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103826 · Cited by 21
Liu, Q., Song, M., Wang, Y., Zhang, P., & Zhang, H. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189341 · Cited by 21
Knopp, T., Jung, R., Wild, J., Bochenek, M. L., Efentakis, P., Lehmann, A., Bieler, T., Garlapati, V. S., Richter, C., Molitor, M., et al. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae046 · Cited by 21
Ironing Out the Mechanism of gp130 Signaling
Osman, E. E. A., & Neamati, N. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001245 · Cited by 21
An emerging role for neutrophils in the pathogenesis of endometriosis
Wilson, T. R., Kasper, S., & Burns, K. A. (2025) · npj Women s Health · doi:10.1038/s44294-025-00059-x · Cited by 21
Prenatal Immune Stress: Its Impact on Brain Development and Neuropsychiatric Disorders
Vasistha, N. A., & Sawa, A. (2025) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-112723-024048 · Cited by 20
Zhu, C., Ding, X., Chen, M., Feng, J., Zou, J., & Zhang, L. (2025) · Biomolecules · doi:10.3390/biom15060893 · Cited by 23
Xu, H., Cao, L., Chen, Y., Zhou, C., Xu, J., Zhang, Z., Li, X., Liu, L., & Lü, J. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02083 · Cited by 20
Huber, A., Allam, A. H., Dijkstra, C., Thiem, S., Huynh, J., Poh, A. R., Konecnik, J., Jacob, S. P., Busuttil, R. A., Liao, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114616 · Cited by 20
Gong, F., Tan, Z., Shan, X., Yang, Y., Tian, S., Zhou, F., Ji, X., & He, Z. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05336 · Cited by 20
Rodríguez-Hernández, M. Á., Baena-Bustos, M., Carneros, D., Zurita-Palomo, C., Muñoz-Pinillos, P., Millán, J., Padillo, F. J., Smerdou, C., von Kobbe, C., Rose‐John, S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105132 · Cited by 19
Self-citationEarly transcriptional effects of inflammatory cytokines reveal highly redundant cytokine networks
Lee, J. J., Yang, L., Kotzin, J. J., Ahimovic, D. J., Bale, M. J., Nigrovic, P. A., Josefowicz, S. Z., Mathis, D. J., Benoist, C. O., Ahimovic, D. J., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241207 · Cited by 19
The role of the JAK/STAT3 signaling pathway in acquired corneal diseases
Song, D., Yang, Q., Li, X., Chen, K., Tong, J., & Shen, Y. (2023) · Experimental Eye Research · doi:10.1016/j.exer.2023.109748 · Cited by 18
At The Interface: Small-Molecule Inhibitors of Soluble Cytokines
Raavi, Koehler, A. N., & Vegas, A. J. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00469 · Cited by 18
Metadata
- Authors
- Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J.
- Affiliations
- Hudson Institute of Medical Research (AU)
- Otto-von-Guericke-Universität Magdeburg (DE)
- Heinrich Heine University Düsseldorf (DE)
- Corresponding author
- Scheller, Jürgen
- Venue
- Nature Reviews Immunology
- Published
- 2023-04-17
- Volume
- 23
- Issue
- 10
- Pages
- 666-681
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC10108826
- OpenAlex
- W4366085911
- Semantic Scholar
- 5ffbde604bb1ef36987e5c29a105b9a8541a3137
- Cited by
- 524
- References
- 213
- Citations by year
- 2026: 146 · 2025: 184 · 2024: 151 · 2023: 43
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (LC170062)
- Deutsche Forschungsgemeinschaft (CRC877, SFB 877, CRC 841, 125440785)
- Deutsche Krebshilfe
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- interleukin-6, IL-6 trans-signalling, soluble IL-6 receptor, gp130, sgp130, IL-6 receptor alpha, inflammatory bowel disease, autoimmune disease, chronic inflammation, cancer, cytokine therapy
- MeSH terms
- Humans, Neoplasms, Interleukin-6, Cytokines, Receptors, Interleukin-6, Cytokine Receptor gp130
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
